Marvin L White
CIK 1493324 · President and CEO · last filed 2026-05-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$832.2K
Companies
4
Total Filings
57
Lifetime Open-Market Net
-$587.6K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EBS | Director | 113,839 | $7.31 | $832.2K | -$1.34M | 17 | 2026-05-04 |
| APVO | President and CEO | 1 | $4.21 | $4 | $685.9K | 29 | 2025-08-08 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Director | — | — | — | $0 | 6 | 2017-03-01 |
| WASHINGTON PRIME GROUP INC. (WPG) Delisted | Director | 556 | $0.83 | $463 | $71.2K | 4 | 2016-05-19 |
Recent Filings · Page 5 of 6
57 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-07-05 | CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-23 | EBS | Disp (D) | −7,833 | $0 | EDGAR |
| 2016-05-20 | EBS | Disp (D) | −7,833 | $0 | EDGAR |
| 2016-05-19 | WASHINGTON PRIME GROUP INC. (WPG) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-12 | CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-03-09 | EBS | Mixed | — | -$607.0K | EDGAR |
| 2016-01-06 | CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-07-13 | CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-23 | WASHINGTON PRIME GROUP INC. (WPG) Delisted | Buy (P) | +5,000 | $71.2K | EDGAR |
| 2015-05-26 | WASHINGTON PRIME GROUP INC. (WPG) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.